Fig 1: A case of breast carcinoma in group 1 (tamoxifen sensitive) with serum AGR2 level 3 ng/ml showed negative SOX2 expression (a) and negative AGR2 expression (b). Another case of group 1 with serum AGR2 level 7 ng/ml showed low SOX2 nuclear positivity score 3 (c) and low AGR2 cytoplasmic positivity score 2 (d) in malignant cells (X100).
Fig 2: Progression-free survival of patients with low or high AGR2 tumor expression is determined using Kaplan-Meier curves. (a) Determination of PFS with respect to AGR2 mRNA levels. There were 4 censored observations in survival curve for low AGR2 mRNA expression and 2 censored observations in survival curve for high AGR2 mRNA level. (b) Determination of PFS with respect to AGR2 IHC staining. There were no censored observations in survival curve for low AGR2 IHC level and 6 censored observations in survival curve for high AGR2 IHC level. Hazard ratio (HR) with 95% CI as well as P value calculated using log-rank test is provided for both curves.
Fig 3: Kaplan-Meier curves assessing the probability of PCa biochemical recurrence after radical prostatectomy by AGR2 and LOX5Blue lines represent: AGR2: Percentage of tumour cells <100% LOX5: No staining. Red lines represent: AGR2: 100% of positive tumour cells, LOX5: >0% staining of positive tumour cells.
Fig 4: Illustration of immunohistochemical detection of AGR2 protein in Tru-Cut needle biopsies. (a) IHC score 80, (b) IHC score 100, (c) IHC score 180, and (d) IHC score 220. As cut-off level determined by ROC analysis was 110, samples (a) and (b) were classified in group denoted as “low” and AGR2 expression and samples (c) and (d) were included in group denoted as “high” AGR2 expression.
Fig 5: Relationship between SOX2 expression (a), AGR2 expression (b), serum AGR2 level (c), and time-to-failure of tamoxifen treatment (in months) in group 2 (Kaplan-Meier survival curves).
Supplier Page from MilliporeSigma for Anti-AGR2 antibody produced in rabbit